SkinBioTherapeutics CEO hails ‘significant scientific milestone’ with cosmetic

‘s () CEO Stuart Ashman speaks to Proactive’s Andrew Scott soon after updating investors on the progress of its cosmetic skincare programme and plans for a psoriasis food supplement trial. Sederma, its partner in the cosmetics programme and a division of (), has successfully replicated the lysate manufacturing process and achieved the same performance from the company’s SkinBiotix technology. They’re now working to validate a scale up of the manufacturing process at different volume levels. Meanwhile he says they’ve established a protocol for its self-managed psoriasis food supplement trial and are proceeding with the study.